Implementation of Ion AmpliSeq in molecular diagnostics

Similar documents
Enterprise Interest I am an employee of ThermoFisher Scientific.

Analytical verification methods for the Oncomine Lung cfdna Assay using the Ion S5 XL System

Functional DNA Quality Analysis Improves the Accuracy of Next Generation Sequencing from Clinical Specimens

A new paradigm in testing for NSCLC-targeted therapies

Accessible answers. Targeted sequencing: accelerating and amplifying answers for oncology research

Controlling Chaos in Oncology Testing

Variant calling workflow for the Oncomine Comprehensive Assay using Ion Reporter Software v4.4

ArcturusXT LCM, ViiA 7, and Ion PGM systems

Oncomine cfdna Assays Part III: Variant Analysis

Processing Ion AmpliSeq Data using NextGENe Software v2.3.0

Sample to Insight. Dr. Bhagyashree S. Birla NGS Field Application Scientist

KAPA hgdna QUANTIFICATION AND QC KIT:

A Crash Course in NGS for GI Pathologists. Sandra O Toole

Detection of Rare Variants in Degraded FFPE Samples Using the HaloPlex Target Enrichment System

Assay Validation Services

Detect low-level somatic mutations in FFPE samples using an extended RAS research assay

Titelstijl van model bewerken

HaloPlex HS. Get to Know Your DNA. Every Single Fragment. Kevin Poon, Ph.D.

Validation of Identity and Ancestry SNP Panels for the Ion PGM

Ion AmpliSeq Designer: Getting Started

QIAseq SPE technology for Illumina : Redefining amplicon sequencing

Precipio, Inc. Instructions for Use. PIK3CA Exon 9 Mutation Analysis using ICE COLD-PCR for Detection with High Resolution Melting

Get to Know Your DNA. Every Single Fragment.

MagMAX FFPE DNA/RNA Ultra Kit

Summary of key processes for tumor BRCA testing. Q&A Session Hadassah Medical Center, Jerusalem Sabine Merkelbach-Bruse

Targeted Sequencing Using Droplet-Based Microfluidics. Keith Brown Director, Sales

with drmid Dx for Illumina NGS systems

Variant detection analysis in the BRCA1/2 genes from Ion torrent PGM data

Welcome to the NGS webinar series

SureSelect Target Enrichment for the Ion Proton TM Next Generation Sequencing System

CAPTURE-BASED APPROACH FOR COMPREHENSIVE DETECTION OF IMPORTANT ALTERATIONS

Create a Planned Run. Using the Ion AmpliSeq Pharmacogenomics Research Panel Plugin USER BULLETIN. Publication Number MAN Revision A.

Applications of the Ion AmpliSeq Immune Repertoire Assay Plus TCRβ

Your Best Data: Teaming QIAGEN Chemistry & Bioinformatics to Drive Samples to Insight

Development and characterization of a high throughput targeted genotypingby-sequencing solution for agricultural genetic applications

Targeted Sequencing in the NBS Laboratory

Access Array BRCA1 / BRCA2 / TP53 Target-Specific Panel Build the highest quality amplicon libraries with qualified assays

Overview of techniques in Molecular Diagnostics ELKE BOONE 23 MAART 2017

Novel methods for RNA and DNA- Seq analysis using SMART Technology. Andrew Farmer, D. Phil. Vice President, R&D Clontech Laboratories, Inc.

NEXT GENERATION SEQUENCING Whole Gene Sequencing

Clinical Molecular Biology A Danish Perspective

Single Nucleotide Variant Analysis. H3ABioNet May 14, 2014

Maximizing your NGS sequencing with IDT. Adam Chernick, PhD Field Applications Manager, Functional Genomics

Amplicon size (bp) E ± SD

SUPPLEMENTARY DATA. Table S1 Clinical features of new SS/MF patients enrolled in SNP6.0 and 10K analysis. % of TCRVß+ within CD3+CD4+

Performance of the Newly Developed Non-Invasive Prenatal Multi- Gene Sequencing Screen

Sequencing and PCR. Training: Ion S5 and S5 XL Systems workflow training

Precipio, Inc. Instructions for Use. EGFR Exon 12 Mutation Enrichment using ICE COLD-PCR

QIAGEN s Preanalytic NGS Solutions

Precipio, Inc. Instructions for Use. EGFR Exon 18 Mutation Enrichment using ICE COLD-PCR

therascreen BRCA1/2 NGS FFPE gdna Kit Handbook Part 2: Analysis

Precipio, Inc. Instructions for Use. EGFR Exon 20 Mutation Analysis using ICE COLD- PCR for Detection with High Resolution Melting

Four things to know before you start your single cell DNA analysis

Next-Generation Sequencing. Technologies

ACCEL-NGS 2S DNA LIBRARY KITS

Incorporating SeqStudio Genetic Analyzer and Sanger sequencing into genome editing workflows

Dried Blood Spot DNA Extraction Guidelines to Ensure Robust Performance in NBS Molecular Assays

Oncomine Tumor Mutation Load Assay

Practical Considerations for Implementation of Clinical Sequencing. Emily Winn-Deen, Ph.D. April 2017

QIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd

Ion S5 and Ion S5 XL Systems

SEQUENCING FROM SAMPLE TO SEQUENCE READY

About Strand NGS. Strand Genomics, Inc All rights reserved.

Targeted Sequencing of Leukemia-Associated Genes Using 454 Sequencing Systems

Ion S5 and Ion S5 XL Systems

Deep Sequencing technologies

Applications and Early Access Results on SeqStudio Genetic Analyzer

TECHNICAL SHEET IDYLLA KRAS MUTATION TEST

Comprehensive NGS Target Enrichment for Medical Research COUNTLESS OPTIONS EZ CHOICE. For Research Use Only. Not for use in diagnostic procedures.

Precipio, Inc. Instructions for Use. BRAF Exon 15 Mutation Analysis using ICE COLD- PCR for Detection with High Resolution Melting

Implementation & development of NGS in the diagnostic lab

Precipio, Inc. Instructions for Use. BRAF Exon 15 Mutation Enrichment using ICE COLD-PCR

Next Generation Oncology Sequencing in your Laboratory. Built by pioneers in cancer genomics and liquid biopsy approaches PROGENEUS

LiquidBiopsy LIQUIDBIOPSY. Automated Rare Template Isolation Platform

Quantidex DNA Assay. Protocol. For Research Use Only. Not for use in diagnostic procedures.

NEBNext Direct Cancer HotSpot Panel

Introducing QIAseq. Accelerate your NGS performance through Sample to Insight solutions. Sample to Insight

Applications of AmpliSeq-based Ion Torrent TCRB Immune Repertoire Sequencing

Incorporating Molecular ID Technology. Accel-NGS 2S MID Indexing Kits

Unique, dual-matched adapters mitigate index hopping between NGS samples. Kristina Giorda, PhD

Human Genome Sequencing Over the Decades The capacity to sequence all 3.2 billion bases of the human genome (at 30X coverage) has increased

From Liquid Biopsy and FFPE Samples to Results

Highly Sensitive, Multiplexed ctdna Mutation Detection on MassARRAY :

Validation of the Oncomine focus panel for next-generation sequencing of clinical tumour samples

Matthew Tinning Australian Genome Research Facility. July 2012

Molecular analysis via next-generation sequencing

From Liquid Biopsy and FFPE Samples to Results

Surely Better Target Enrichment from Sample to Sequencer

TaqMan Assays for genetic variation research. Superior performance reliable, robust solutions

MHC Region. MHC expression: Class I: All nucleated cells and platelets Class II: Antigen presenting cells

Next Generation Sequencing. Target Enrichment

Next Generation Sequencing of CFTR from dried blood spots using the Ion Torrent PGM

Lab methods: Exome / Genome. Ewart de Bruijn

Next Generation Sequencing: Data analysis for genetic profiling

HLA-Typing Strategies

SNP calling. Jose Blanca COMAV institute bioinf.comav.upv.es

SureSelect XT HS. Target Enrichment

EPIGENTEK. Methylamp Whole Cell Bisulfite Modification Kit. Base Catalog # P-1016 PLEASE READ THIS ENTIRE USER GUIDE BEFORE USE

Performance Characteristics drmid Dx for Illumina NGS systems

Surely Better Target Enrichment from Sample to Sequencer and Analysis

Transcription:

Implementation of Ion AmpliSeq in molecular diagnostics The Rotterdam Experience Ronald van Marion Deelnemersbijeenkomst SKML sectie Pathologie Amersfoort, 26 mei 2016

Molecular Diagnostics in Rotterdam Past Mutation detection by Sanger Sequencing, 1 amplicon/reaction Present More targets, less material > NGS, 100s amplicons/reaction Ion Torrent platform, First PGM purchased in April 2012, 2 nd in December 2013 Fully implemented in diagnostics in mid 2013

Ion AmpliSeq technology Highly multiplexed custom primer panels used in PCR Current diagnostics: 300 700 amplicons Primer design Library preparation Library quantification Emulsion PCR Chip loading & sequencing Data analysis and reporting

Ion Torrent AmpliSeq workflow Highly multiplexed PCR in 2 reactions Adapter ligation Clonal amplification by emulsion PCR Sequencing on Ion chip

DNA isolation from routine specimens Paraffin block H&E stained section Cytology preparation Paraffin section IHC stained section

DNA isolation Selection of tumor cells by pathologist, as high as possible Manual microdissection from haematoxylin slides

Manual microdissection Use 1 10 slides depending on number of cells

DNA isolation Day 1 Manual microdissection Cell lysis + proteinase K treatment overnight at 56 degrees Day 2 Spin down cell debris Measure quantity Quality is not checked beforehand

DNA quantity According to protocol 10 ng per primer pool is needed Difficult when using small biopsies or cytology samples Test performance with 10 ng, 1 ng and 0.1 ng DNA

Detected variants 10 ng Chr Position Gene Type Ref Variant Var Freq Coverage 2 29443623 ALK SNP G A 52 2680 3 178936091 PIK3CA SNP G A 42 4861 4 1807894 FGFR3 SNP G A 100 5588 4 55141055 PDGFRA SNP A G 100 1315 5 112175770 APC SNP G A 100 3095 7 55249063 EGFR SNP G A 100 49 10 43613843 RET SNP G T 100 2787 10 89711833 PTEN INS A AT 28 1905 11 534242 HRAS SNP A G 52 2821 13 28610183 FLT3 SNP A G 100 6521 17 7578210 TP53 SNP T C 27 3531 17 7579472 TP53 SNP G C 99 2527 1 ng Chr Position Gene Type Ref Variant Var Freq Coverage 2 29443623 ALK SNP G A 51 3329 3 178936091 PIK3CA SNP G A 42 5485 4 1807894 FGFR3 SNP G A 100 6542 4 55141055 PDGFRA SNP A G 100 1694 5 112175770 APC SNP G A 100 4483 7 55249063 EGFR SNP G A 100 1219 10 43613843 RET SNP G T 100 2702 11 534242 HRAS SNP A G 56 4067 13 28610183 FLT3 SNP A G 100 7327 17 7578210 TP53 SNP T C 26 3805 17 7579472 TP53 SNP G C 100 2941 0,1 ng Chr Position Gene Type Ref Variant Var Freq Coverage 2 29443623 ALK SNP G A 55 2097 3 178936091 PIK3CA SNP G A 36 4061 4 1807894 FGFR3 SNP G A 100 5052 4 55141055 PDGFRA SNP A G 100 1243 5 112175770 APC SNP G A 100 2778 7 55249063 EGFR SNP G A 99 185 10 43613843 RET SNP G T 100 1700 11 534242 HRAS SNP A G 41 2131 13 28610183 FLT3 SNP A G 100 6905 17 7578210 TP53 SNP T C 38 3346 17 7579472 TP53 SNP G C 99 2394

Homopolymers difficult on Ion Torrent platform

PIK3CA, p.e545k 10 ng 58% G / 42% A 1 ng 58% G / 42% A 0,1 ng 64% G / 36% A

DNA quality Not tested beforehand DNA isolated from FFPE material can be heavily fragmented resulting in decreased read length

DNA quality Cytosine deamination give rise to false positives C>T transitions C U T Cytosin Uracil

False positives due to cytosine deamination Usually allele frequency below 10%

Primer design Ion AmpliSeq Designer As much coverage of ROI with as few amplicons as possible (cost) Best possible design with a set of rules Optimal melting temperature No homopolymers in primer sequence Avoid repeat regions GC content between 20-80% No known dbsnp allowed in primer (MAF > 5%) Pseudogenes No interaction between primers in one pool

Primer design Confirm ROIs are covered What to do with missed region? Accept, White glove, Spike primer, Use other techniques (Sanger Sequencing, SNaPshot, mutation specific PCR etc)

Quality test of primers In silico in vitro Coverage of all (important) amplicons? Torrent Suite CoverageAnalysis plugin

Ion AmpliSeq Designer v3.4 Visualize mapped reads in viewer

Ion AmpliSeq Designer v4.2.4 Visualize mapped reads in viewer

Ion AmpliSeq Designer v3.4 In silico PCR check of primers

Ion AmpliSeq Designer v4.2.4 In-silico PCR check of primers

Low mapping quality CoverageAnalysis alone is not enough to validate primers

Mispriming

Mispriming HRAS exon 2 forward primer C G C C A G G C T C A C C T C T A T A G Described in McCall et al, JMD, 2014

Quality test of primers Coverage all (important) amplicons? Check mutation detection in as much amplicons as possible Commercial test samples available from e.g. Horizon Diagnostics and Acrometrix

Horizon Diagnostics HDx Reference Standard Allele frequencies in three tiers: 5%, 2,5% and 1,25% Available as FFPE material

Acrometrix Oncology Hotspot Control Synthetic and genomic DNA variants in 5 35 % allele frequency > 500 COSMIC mutations are present Suitable for commercial and custom primer sets

Acrometrix Oncology Hotspot Control

Acrometrix Oncology Hotspot Control Missed TP53 mutation in run 2 AF below reporting threshold

Data analysis Choice of software Torrent Suite VariantCaller, no annotation Ion Reporter Other (commercial) software packages Huge number of settings in software Balance between false positives and missed mutations

Data analysis, different software, different results Validation of Seqnext software (JSI Medisys) Compare Torrent Suite VariantCaller to Seqnext

Data analysis, different software, different results Reanalysis of 181 samples, 2 different amplicon panels PANEL 1, 101 amplicons 97 samples 95 concordant 4 novel mutations PANEL 2, 255 amplicons 84 samples 81 concordant 1 novel mutation All novel mutations are confirmed by Sanger Sequencing Difficult to select the best parameter set that detects all variants without false positives

Interpretation of variants Quality parameters Coverage > 100 Ok 20-100 KMBP decides < 20 Ignore, confirm if relevant Variant allele frequency 1 / 2 x % tumor cells Ok > 1 / 2 x % tumor cells Allelic imbalance < 1 / 2 x % tumor cells Check tumor cell %, possibly minor clone < 5 %, gene of interest KMBP decides, confirmation difficult < 5 %, no gene of interest unreliable

Interpretation of variants Strand bias 5:1 1:5 Can be amplicon dependent and present in all samples Homopolymers No insertions or deletions in homopolymer

Reporting All quality parameters are met Known variants based on literature, COSMIC or LOVD are reported Variants of unknown significance, KMBP decides optional: Confirm by Sanger Sequencing Exclude germ line variant by testing normal DNA

Thank you for your attention